Physician profile
Phillip W Covington
NPI 1720139215
$14,925.84
in general payments reported to CMS, 2019-2025
59 companies · $3,123 in 2025
The $3,123 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,453 · 2022: $2,514 · 2023: $3,670 · 2024: $2,166 · 2025: $3,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,958.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,111.73 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,447.65 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,343.79 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $1,140.12 | 2021-2025 | |
| Glaxosmithkline, LLC. | $858.89 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $689.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $607.25 | 2021-2025 | |
| Lilly USA, LLC | $589.96 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Axsome Therapeutics, INC. | $565.40 | 2023-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.63 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $347.53 | 2021-2023 | |
| Esperion Therapeutics, INC. | $313.03 | 2021-2025 | Nexletol |
| Abbott Laboratories | $309.17 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Idorsia Pharmaceuticals US INC | $285.68 | 2022-2023 | Quviviq |
| Preventric Diagnostics, INC. | $273.82 | 2021 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Covington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.